Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

Transplantation Proceedings

Volumn 29, Issue 1-2, 1997, Pages 809-811

  Brennan, D C ^a,b   Garlock, K A ^a   Lippmann, B J ^a   Buller, R S ^a   Gaudreault Keener, M ^a   Lowell, U A ^a   Miller, S B ^a   Shenoy, S ^a   Howard, T K ^a   Storch, G A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Transplant Nephrology 6107 Queeny Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; KIDNEY TRANSPLANTATION; MORBIDITY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS CULTURE; VIRUS LATENCY;

EID: 12644276434     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(96)00143-1     Document Type: Conference Paper

References (3)

1. Farrugia E, Schwab TR: Mayo Clin Proc 67:879, 1992
2. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al: Transplantation 53:68, 1992
3. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al: Ann Int Med 123:18, 1995